Skip to main content

Year: 2024

Netcompany – Interim report for the nine months ended 30 September 2024

Company announcement No. 48/2024                                                  31 October 2024 Continued growth and improved marginSummaryIn Q3 2024, Netcompany grew revenue by 10.4% (constant 10.4%) to DKK 1,613.9m. Adjusted EBITDA increased by 39.3% (constant 40.1%) to DKK 306.3m in Q3 2024. Adjusted EBITDA margin was 19% in Q3 2024 (constant 19.1%) compared to 15% in Q3 2023. Average number of full-time employees increased by 328 FTEs from 7,760 in Q3 2023 to 8,088 in Q3 2024. Free cash flow was DKK 145.3m in Q3 2024 compared to DKK 100.4m in Q3 2023. Cash conversion ratio was 89.5% in Q3 2024. Debt leverage was 1.5x in Q3 2024. Netcompany maintains expectations for full year.“In Q3, we grew revenue by 10.4%, once again supported by ongoing recovery in the Danish part of the Group combined with strong growth in Netcompany-Intrasoft,...

Continue reading

ING posts 3Q2024 net result of €1,880 million, supported by commercial growth and strong income

ING posts 3Q2024 net result of €1,880 million,supported by commercial growth and strong income  3Q2024 profit before tax of €2,668 million with a four-quarter rolling average return on equity of 13.8%• Resilient net interest income, supported by volume growth in lending and deposits• Fee income increasing 11% year-on-year, surpassing €1 billion, with significant growth in both Retail and Wholesale Banking• Increase of 189,000 mobile primary customers and strong growth in mortgages• €2.5 billion distribution announced as we continue to align our capital to our target level CEO statement “In the third quarter of 2024, we have again delivered strong results and are executing well on our strategy to accelerate growth, increase impact and deliver value for all stakeholders,” said Steven van Rijswijk,...

Continue reading

SPIE – Press release – Quarterly information as at September 30th, 2024

Cergy, October 31st, 2024 Strong 9m 2024 organic growth (+4.4%) including a solid level of organic growth in Q3 (at +1.7%)9m 2024 revenue: €7,130.7 million, up +13.9% year-on-year (including +4.4% organic and +9.4% contribution from bolt-on acquisitions) Q3 2024 revenue up +13.1% including +1.7% organic growth:Very strong performance in Germany and The Netherlands while France remained particularly solid Weak quarter in Central Europe due to contract phasing in Poland and high comparison basis in Switzerland After an exceptional contribution of a shutdown operation in H1 2024, Global Services Energy back to more normative growth on an extremely strong comparison basisWe continue to observe very solid underlying trends in our markets driven by the energy transition while, as expected, our topline reflects a lower cost inflation...

Continue reading

ONWARD ARC-EX® System Named One of TIME’s Best Inventions of 2024

EINDHOVEN, the Netherlands, Oct. 31, 2024 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its investigational ARC-EX System has been named one of TIME’s Best Inventions of 2024. “We are grateful for TIME’s recognition of the ARC-EX System, which has the potential to impact hundreds of thousands of people with spinal cord injury and impaired hand and arm function,” said Dave Marver, CEO of ONWARD Medical. “SCI is a devastating injury that can change lives in an instant. We are hopeful ARC-EX Therapy is just the first of many innovative therapies ONWARD Medical can introduce for the benefit of the Spinal Cord Injury Community.” TIME’s...

Continue reading

Societe Generale: Third quarter 2024 earnings

RESULTS AT 30 SEPTEMBER 2024Press release                                                        Paris, 31 October 2024 SOLID BUSINESS PERFORMANCE IN Q3 24,GROUP NET INCOME OF EUR 1.4 BILLION Revenues of EUR 6.8 billion, up +10.5% vs. Q3 231, driven notably by the strong rebound in net interest income in France, in line with end of year estimate, and by another solid performance of Global Banking and Investor Solutions, in particular in Equities and Transaction Banking Strong positive jaws, control of operating expenses, down by -0.8% vs. Q3 23 Cost-to-income ratio at 63.3% in Q3 24, improved by 7.1 points vs. Q3 23 Stable cost of risk at 27 basis points in Q3 24 Profitability (ROTE) at 9.6% vs. 3.8% for Q3 23 9M 24 NET INCOME UP 53% VS. 9M 23 AT EUR 3.2 BILLION,DRIVEN BY THE IMPROVEMENT IN OPERATING PERFORMANCE Revenues of EUR 20.2...

Continue reading

Fanhua Announces Change of Name to AIX Inc. and the Results of its Extraordinary General Meeting

GUANGZHOU, China, Oct. 31, 2024 (GLOBE NEWSWIRE) — Fanhua Inc. (Nasdaq: AIFU) (the “Company” or “Fanhua”), a leading independent technology-driven financial services provider in China, today announced the results of its extraordinary general meeting of shareholders held in Guangzhou on October 31, 2024 at 9:00am Beijing Time. At the extraordinary general meeting, each of the following resolutions submitted for shareholder approval was adopted, and after the adoption of the proposed resolutions, all corporate authorizations and actions contemplated thereunder were approved: (i) THAT the Company’s English name be changed from “Fanhua Inc.” to “AIX Inc.” and dual foreign (Chinese) name be changed from “泛华控股集团” to “智能未来有限公司”, respectively, (ii) THAT the authorized share capital of the Company, which is currently US$10,000,000 divided...

Continue reading

Covenant Logistics Group Named 2024 Top Company for Women to Work in Transportation

Being named a 2024 ‘Top Company for Women to Work in Transportation is a prestigious honor and a valuable third-party validation that your company is an exceptional workplace for women in all roles. CHATTANOOGA, Tenn., Oct. 31, 2024 (GLOBE NEWSWIRE) — Covenant Logistics Group, Inc. (NYSE: CVLG) is proud to announce its recognition as a 2024 “Top Company for Women to Work in Transportation” by Redefining the Road, the official magazine of the Women In Trucking Association (WIT). This prestigious honor highlights Covenant’s commitment to an inclusive and supportive work environment, driven by its core values of empathy, servanthood, and virtue. Companies recognized by Redefining the Road share key traits: fostering diverse workplaces, offering competitive compensation, flexible work requirements, and providing professional...

Continue reading

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has entered into a securities purchase agreement for the purchase and sale of 5,263,158 common shares at a purchase price of $0.95 per share pursuant to a registered direct offering, resulting in gross proceeds of approximately $5 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about November 1, 2024,...

Continue reading

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium Australia Study is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of yearDANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study, known as ICoN-1, has been cleared to proceed by the Therapeutic Goods Administration (TGA) in Australia, and by healthcare authorities in three additional...

Continue reading

Athabasca Oil Announces 2024 Third Quarter Results Highlighted by Strong Free Cash Flow and Continued Execution on Share Buybacks

CALGARY, Alberta, Oct. 30, 2024 (GLOBE NEWSWIRE) — Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) is pleased to report its third quarter results highlighting strong free cash flow underpinned by operational momentum at all assets and continued execution on its return of capital commitment through share buybacks. Corporate Consolidated Third Quarter HighlightsProduction: Average production of 38,909 boe/d (98% Liquids), representing 8% growth year over year (16% on a per share basis). Annual production remains on track with previously increased 2024 guidance of 36,000 – 37,000 boe/d. Cash Flow Growth: Adjusted Funds Flow of $164 million (cash flow from operating activities of $187 million) or $0.30 per share, representing 25% growth on a per share basis year over year. In 2024, the Company forecasts Adjusted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.